Advertisement

Topics

22nd Century Granted FDA Guidance Meeting for X-22 Smoking Cessation Aid

06:59 EST 2 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is focused on reducing the harm caused by smoking, announced today that the Company has been granted a guidance meeting with the Center for Drug Evalu...

Other Sources for this Article

Investor Relations:
IRTH Communications
Andrew Haag, 866-976-4784
xxii@irthcommunications.com

NEXT ARTICLE

More From BioPortfolio on "22nd Century Granted FDA Guidance Meeting for X-22 Smoking Cessation Aid"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...